Advanced breast cancer An update to systemic therapy

被引：1

作者：

Carson, Emma ^{[1
,2
]}

Dear, Rachel ^{[1
,3
]}

机构：

[1] St Vincents Hosp, Kinghorn Canc Ctr, Darlinghurst, NSW, Australia

[2] Univ New South Wales, Sydney Med Sch, Sydney, NSW, Australia

[3] Univ Sydney, Sydney Med Sch, Chris OBrien Lifehouse, Camperdown, NSW, Australia

来源：

AUSTRALIAN JOURNAL OF GENERAL PRACTICE | 2019年 / 48卷 / 05期

关键词：

POSTMENOPAUSAL WOMEN; DOUBLE-BLIND; 1ST-LINE THERAPY; PHASE-III; PLUS; TRASTUZUMAB; ABEMACICLIB; FULVESTRANT; EXEMESTANE; TAMOXIFEN;

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Background Breast cancer is the most common cancer in women in Australia. Breast cancer is a heterogeneous disease; subtypes are defined by their biology with prognostic and therapeutic implications. Advancements in treatment have led to improved survival and quality of life for patients with advanced breast cancer. Objective The aim of this article is to provide a concise update regarding the current systemic management of advanced breast cancer, including novel treatment options. Discussion The aim of treatment in advanced breast cancer is to prolong life, manage symptoms and improve quality of life. The general practitioner is an important member of the patient's multi-disciplinary team.

引用

页码：278 / 283

页数：6

共 31 条

[1] Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials [J].

Albain, K. ;

Anderson, S. ;

Arriagada, R. ;

Barlow, W. ;

Bergh, J. ;

Bliss, J. ;

Buyse, M. ;

Cameron, D. ;

Carrasco, E. ;

Clarke, M. ;

Correa, C. ;

Coates, A. ;

Collins, R. ;

Costantino, J. ;

Cutter, D. ;

Cuzick, J. ;

Darby, S. ;

Davidson, N. ;

Davies, C. ;

Davies, K. ;

Delmestri, A. ;

Di Leo, A. ;

Dowsett, M. ;

Elphinstone, P. ;

Evans, V. ;

Ewertz, M. ;

Gelber, R. ;

Gettins, L. ;

Geyer, C. ;

Goldhirsch, A. ;

Godwin, J. ;

Gray, R. ;

Gregory, C. ;

Hayes, D. ;

Hill, C. ;

Ingle, J. ;

Jakesz, R. ;

James, S. ;

Kaufmann, M. ;

Kerr, A. ;

MacKinnon, E. ;

McGale, P. ;

McHugh, T. ;

Norton, L. ;

Ohashi, Y. ;

Paik, S. ;

Pan, H. C. ;

Perez, E. ;

Peto, R. ;

Piccart, M. .

LANCET, 2012, 379 (9814) :432-444

[2]

[Anonymous], 2018, PLYM M

[3]

Bonneterre J, 2001, CANCER, V92, P2247, DOI 10.1002/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO

[4]

2-Y

[5]

Cancer Australia, 2018, BREAST CANC STAT

[6] 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) [J].

Cardoso, F. ;

Costa, A. ;

Senkus, E. ;

Aapro, M. ;

Andre, F. ;

Barrios, C. H. ;

Bergh, J. ;

Bhattacharyya, G. ;

Biganzoli, L. ;

Cardoso, M. J. ;

Carey, L. ;

Corneliussen-James, D. ;

Curigliano, G. ;

Dieras, V. ;

El Saghir, N. ;

Eniu, A. ;

Fallowfield, L. ;

Fenech, D. ;

Francis, P. ;

Gelmon, K. ;

Gennari, A. ;

Harbeck, N. ;

Hudis, C. ;

Kaufman, B. ;

Krop, I. ;

Mayer, M. ;

Meijer, H. ;

Mertz, S. ;

Ohno, S. ;

Pagani, O. ;

Papadopoulos, E. ;

Peccatori, F. ;

Penault-Llorca, F. ;

Piccart, M. J. ;

Pierga, J. Y. ;

Rugo, H. ;

Shockney, L. ;

Sledge, G. ;

Swain, S. ;

Thomssen, C. ;

Tutt, A. ;

Vorobiof, D. ;

Xu, B. ;

Norton, L. ;

Winer, E. .

ANNALS OF ONCOLOGY, 2017, 28 (01) :16-33

[7] Double-blind, Randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: Results from EFECT [J].

Chia, Stephen ;

Gradishar, William ;

Mauriac, Louis ;

Bines, Jose ;

Amant, Frederic ;

Federico, Miriam ;

Fein, Luis ;

Romieu, Gilles ;

Buzdar, Aman ;

Robertson, John F. R. ;

Brufsky, Adam ;

Possinger, Kurt ;

Rennie, Pamela ;

Sapunar, Francisco ;

Lowe, Elizabeth ;

Piccart, Martine .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1664-1670

[8] Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial [J].

Cristofanilli, Massimo ;

Turner, Nicholas C. ;

Bondarenko, Igor ;

Ro, Jungsil ;

Im, Seock-Ah ;

Masuda, Norikazu ;

Colleoni, Marco ;

DeMichele, Angela ;

Loi, Sherene ;

Verma, Sunil ;

Iwata, Hiroji ;

Harbeck, Nadia ;

Zhang, Ke ;

Theall, Kathy Puyana ;

Jiang, Yuqiu ;

Bartlett, Cynthia Huang ;

Koehler, Maria ;

Slamon, Dennis .

LANCET ONCOLOGY, 2016, 17 (04) :425-439

[9] Phase II Study of Paclitaxel Given Once per Week Along With Trastuzumab and Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer [J].

Dang, Chau ;

Iyengar, Neil ;

Datko, Farrah ;

D'Andrea, Gabriella ;

Theodoulou, Maria ;

Dickler, Maura ;

Goldfarb, Shari ;

Lake, Diana ;

Fasano, Julie ;

Fornier, Monica ;

Gilewski, Theresa ;

Modi, Shanu ;

Gajria, Devika ;

Moynahan, Mary Ellen ;

Hamilton, Nicola ;

Patil, Sujata ;

Jochelson, Maxine ;

Norton, Larry ;

Baselga, Jose ;

Hudis, Clifford .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (05) :442-U89

[10] Combination versus sequential single agent chemotherapy for metastatic breast cancer [J].

Dear, Rachel F. ;

McGeechan, Kevin ;

Jenkins, Marisa C. ;

Barratt, Alexandra ;

Tattersall, Martin H. N. ;

Wilcken, Nicholas .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (12)

← 1 2 3 4 →